Cibus (CBUS) Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024 summary
Event summary combining transcript, slides, and related documents.
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024 summary
2 Feb, 2026Industry leadership and technology overview
Leading advancements in agricultural gene editing, focusing on traits that improve farming efficiency and sustainability.
Gene editing enables precise, small changes in plant genomes, making crops indistinguishable from those bred conventionally.
Regulatory acceptance is growing, with over 18 countries harmonizing policies to treat gene-edited crops like traditional varieties.
Technology allows for rapid trait insertion, with turnaround times as short as 12 months for new seed traits.
High conversion rates in gene editing, achieving up to 50% efficiency in some manufacturing processes.
Regulatory and market developments
U.S., Europe, and Canada now consider gene-edited crops as conventional, streamlining approvals and market entry.
European Parliament has passed supportive legislation, expected to be fully enacted by early next year.
Global harmonization of gene editing regulations is facilitating international trade and adoption.
Approval processes focus on varietal registration and quality assurance rather than lengthy drug-like approvals.
Customers are seed companies, who rapidly integrate new traits and launch products within 1-2 years, reaching saturation in 3 years.
Product pipeline and commercialization
Herbicide tolerance traits (HT1, HT3) are being adopted in rice and other crops, with major customers like Nutrien and Latin American partners signed on.
Stacked gene-edited traits enable more effective weed management and are a first in the industry.
Field trials in the U.K. for pod shatter reduction in oilseed rape are underway, with results expected in Q3.
Specialty ingredients and bio-fragrances are in development, with first shipments of bio-fragrances expected this year.
Sustainable ingredients will launch after completion of the soybean platform.
Latest events from Cibus
- Advanced Rice and ingredient programs, cut costs, and raised funds for 2026 milestones.CBUS
Q4 202517 Mar 2026 - Gene-edited crop traits target global markets, with royalties expected from 2026 onward.CBUS
17th Annual LD Micro Main Event Conference3 Feb 2026 - Q2 2024 saw commercial expansion, advanced trait milestones, and a $28.5M net loss.CBUS
Q2 20242 Feb 2026 - Gene editing traits for major crops are poised for rapid global adoption and strong royalty growth.CBUS
Sidoti Micro-Cap Virtual Conference2 Feb 2026 - Q3 net loss of $201.5M from goodwill impairment; cost savings and commercialization ongoing.CBUS
Q3 202415 Jan 2026 - Industrialized gene editing and royalty-driven traits set the stage for scalable agtech growth.CBUS
Sidoti Micro-Cap Virtual Conference9 Jan 2026 - Q4 2024 net loss narrowed, cash runway extended, and gene editing platforms advanced.CBUS
Q4 202424 Dec 2025 - Net loss widened to $49.4M on impairment, with cash needs beyond Q3 2025 despite revenue growth.CBUS
Q1 202527 Nov 2025 - Gene-edited crop traits set for 2027 launch, driving royalty growth and global market access.CBUS
Alliance Global Partners Healthcare Company Showcase25 Nov 2025